Get the Stockscreener App
13.99
2.17%
-0.31
After Hours:
13.99
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $13.99, with a volume of 1.44M.
It is down -2.17% in the last 24 hours and down -11.16% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$14.30
Open:
$14.05
24h Volume:
1.44M
Relative Volume:
1.85
Market Cap:
$2.34B
Revenue:
$3.47B
Net Income/Loss:
$668.83M
P/E Ratio:
3.767
EPS:
3.7138
Net Cash Flow:
$253.46M
1W Performance:
-1.76%
1M Performance:
-11.16%
6M Performance:
+1.49%
1Y Performance:
+2.46%
1-Day Range:
$13.93
$14.25
1-Week Range:
$13.93
$14.40
52-Week Range:
$12.90
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RDY | 13.99 | 2.34B | 3.47B | 668.83M | 253.46M | 3.7138 |
| ZTS | 176.71 | 79.55B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.55 | 43.18B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.33 | 42.26B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.08 | 19.35B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Weekly Upgrades and Downgrades - InvestorPlace
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - MSN
Jharkhand Elections Phase 2: Richest candidate declares assets worth Rs 402 cr – Check list of top 10 wealthiest candidates - The Financial Express
Jharkhand Phase 2 Elections 2024: 122 candidates with serious criminal cases get tickets, shows ADR report - The Financial Express
ADR, GDR Listings of Indian companies - Goodreturns
Earnings call: Dr. Reddy's reports robust growth and strategic expansions By Investing.com - Investing.com Australia
Earnings call: Dr. Reddy's reports robust growth and strategic expansions - Investing.com India
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type - GlobeNewswire Inc.
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA By Investing.com - Investing.com South Africa
Dr. Reddy’s Labs ADR earnings missed by $0.85, revenue topped estimates - Investing.com Australia
Asian Equities Traded in the US as American Depositary Receipts Climb Higher Friday - MSN
Dr. Reddy’s shares trade ex-split today. Stock up 2% - The Economic Times
Maharashtra: 93% MLAs crorepatis, 60% with criminal cases against them – know the composition of outgoing assembly | Mint - Mint
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading - MSN
Indian stock market: 8 things that changed for market overnight- Gift Nifty, US retail sales, ECB rate cut to Q2 results | Stock Market News - Mint
Infosys, Wipro ADRs down 3% on NYSE after Q2 results even as S&P, Dow drift near record-highs | Stock Market News - Mint
Q2 Results Updates: Infosys ADR Falls Over 3%, Wipro Down Over 4% - NDTV Profit
Top gainers and losers for today on October 16: HDFC Life, Dr Reddy’s Labs, Grasim lead NIFTY movers - Upstox
1:5 Stock Split By Large-Cap Pharma Stock; Record DateOct 28: Buy Dr Reddy's For Rs 7,300 Target - Goodreturns
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Saudi Arabia Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Haryana Election 2024: 95 candidates have serious criminal cases against them, 11 with cases of crime against women, says report - The Financial Express
Side-effects of banned drug Nimesulide still reported in children: Report | Today News - Mint
Dr. Reddy’s Announces Share Subdivision Date - TipRanks
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug - Business Standard
Haryana Elections 2024: Capt. Abhimanyu, Savitri Jindal among wealthiest candidates for October 5 polls | Mint - Mint
Assam: Mobile internet services to be disabled for eight hours on Sunday, here's why | Today News - Mint
Announcements Updates: Compliances-Reg. 39 (3)Details of Loss of Certificate / Duplicate Certificate - The Economic Times
Apni Party's Altaf Bukhari, BJP's Devender Rana among 3 richest candidates in Jammu and Kashmir assembly poll fray | Mint - Mint
Dr. Reddy's Labs ADR Sees RS Rating Rise To 72 - Investor's Business Daily
Dr. Reddy’s Empowers Employees with Stock Options - TipRanks
Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Radiopharm Theranostics Limited - Business Wire
Mondrian Investment Partners LTD Has $11.56 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr. Reddy's Laboratories Share Price Today Live Updates: Dr. Reddy's Laboratories Sees 1.48% Decline, Cu... - The Economic Times
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories Sees Minor Price Dip Amidst ... - The Economic Times
Dr. Reddy’s Shareholders Approve Stock Split - TipRanks
US FDA closes inspection of Dr Reddy’s API unit - BusinessLine
Singapore Anticoagulant Reversal Drugs Market Size & Outlook, 2027 - Grand View Research
Mexico Antiviral Drugs Market Size & Outlook, 2022-2030 - Grand View Research
The United States Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Latin America Antiviral Drugs Market Size & Outlook, 2030 - Grand View Research
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? - Investor's Business Daily
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):